Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Portage Biotech Inc PRTG

Healthcare Biotechnology
Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is engaged in advancing therapies to improve long-term treatment response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through... see more

Recent & Breaking News (NDAQ:PRTG)

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update

GlobeNewswire August 27, 2024

Portage Biotech Reports Fiscal Year-Ended March 31, 2024 Financial Results and Business Update

GlobeNewswire August 15, 2024

Portage Biotech Announces 1-for-20 Reverse Stock Split

GlobeNewswire August 13, 2024

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

GlobeNewswire April 12, 2024

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

GlobeNewswire March 26, 2024

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

GlobeNewswire February 28, 2024

Portage Biotech Reports Business and Strategic Update

GlobeNewswire January 4, 2024

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update

GlobeNewswire November 28, 2023

Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

GlobeNewswire November 6, 2023

Portage Biotech Announces $6.0 Million Registered Direct Offering

GlobeNewswire September 29, 2023

Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

GlobeNewswire September 20, 2023

Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors

GlobeNewswire September 5, 2023

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update

GlobeNewswire August 30, 2023

Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update

GlobeNewswire July 31, 2023

Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors

GlobeNewswire June 26, 2023

Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire June 5, 2023

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

GlobeNewswire June 1, 2023

Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire April 26, 2023

Portage Biotech to Present at Oppenheimer's 33rd Annual Healthcare Conference

GlobeNewswire March 7, 2023

Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022

GlobeNewswire March 1, 2023